Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15999981 | 0.93 | PPARG (0.68) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14122312 | 0.83 | PPARG (1.00) | PPARGEPHX2 | |
| SCHEMBL4539264 | 0.80 | PPARG (1.00) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15999985 | 0.78 | PPARG (0.73) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15999982 | 0.77 | PPARG (0.71) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8035855 | 0.77 | PPARG (0.67) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL4564519 | 0.76 | PPARG (0.66) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15999976 | 0.75 | PPARG (0.72) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15999975 | 0.75 | PPARG (0.72) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15999964 | 0.73 | PPARG (0.74) | PPARGEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249196-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2014-09-04 | — | — | US | disclosed |
| US-20140249196-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249196-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | PPARG, CDK5, CDK5R1 | PPARG 1/4885CYP1A2 3318/4885CYP3A4 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.